JP6035423B2 - 新規な縮合ピリミジン化合物又はその塩 - Google Patents

新規な縮合ピリミジン化合物又はその塩 Download PDF

Info

Publication number
JP6035423B2
JP6035423B2 JP2015531804A JP2015531804A JP6035423B2 JP 6035423 B2 JP6035423 B2 JP 6035423B2 JP 2015531804 A JP2015531804 A JP 2015531804A JP 2015531804 A JP2015531804 A JP 2015531804A JP 6035423 B2 JP6035423 B2 JP 6035423B2
Authority
JP
Japan
Prior art keywords
amino
group
oxazol
pyrimidine
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015531804A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2015022926A1 (ja
Inventor
聡 井口
聡 井口
文仁 細井
文仁 細井
武 相良
武 相良
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of JP6035423B2 publication Critical patent/JP6035423B2/ja
Publication of JPWO2015022926A1 publication Critical patent/JPWO2015022926A1/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2015531804A 2013-08-12 2014-08-11 新規な縮合ピリミジン化合物又はその塩 Active JP6035423B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013167600 2013-08-12
JP2013167600 2013-08-12
PCT/JP2014/071158 WO2015022926A1 (ja) 2013-08-12 2014-08-11 新規な縮合ピリミジン化合物又はその塩

Publications (2)

Publication Number Publication Date
JP6035423B2 true JP6035423B2 (ja) 2016-11-30
JPWO2015022926A1 JPWO2015022926A1 (ja) 2017-03-02

Family

ID=52468312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015531804A Active JP6035423B2 (ja) 2013-08-12 2014-08-11 新規な縮合ピリミジン化合物又はその塩

Country Status (22)

Country Link
US (1) US9580432B2 (enExample)
EP (1) EP2947086B1 (enExample)
JP (1) JP6035423B2 (enExample)
KR (1) KR101828187B1 (enExample)
CN (1) CN105452257B (enExample)
AU (1) AU2014307437B2 (enExample)
BR (1) BR112016002069B1 (enExample)
CA (1) CA2921208C (enExample)
DK (1) DK2947086T3 (enExample)
ES (1) ES2661733T3 (enExample)
HU (1) HUE036834T2 (enExample)
MX (1) MX360498B (enExample)
MY (1) MY171831A (enExample)
NO (1) NO2947086T3 (enExample)
PH (1) PH12015502737B1 (enExample)
PL (1) PL2947086T3 (enExample)
PT (1) PT2947086T (enExample)
RU (1) RU2666349C2 (enExample)
SG (1) SG11201600048VA (enExample)
TR (1) TR201802875T4 (enExample)
TW (1) TWI585089B (enExample)
WO (1) WO2015022926A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014308616B2 (en) 2013-08-23 2018-12-06 Neupharma, Inc. Certain chemical entities, compositions, and methods
HUE038041T2 (hu) 2015-01-30 2018-10-29 Taiho Pharmaceutical Co Ltd Fuzionált pirimidin vegyület új sója és annak kristálya
MX381234B (es) * 2015-01-30 2025-03-12 Taiho Pharmaceutical Co Ltd Agente preventivo y/o terapéutico de enfermedad inmune.
MY191938A (en) * 2015-09-01 2022-07-19 Taiho Pharmaceutical Co Ltd Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof
MA41559A (fr) * 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
TWI642671B (zh) * 2015-10-28 2018-12-01 台灣神隆股份有限公司 依魯替尼之製備方法及其中間體
PL3269370T3 (pl) 2016-02-23 2020-06-01 Taiho Pharmaceutical Co., Ltd. Nowy skondensowany związek pirymidynowy lub jego sól
JP7101165B2 (ja) * 2016-08-15 2022-07-14 ニューファーマ， インコーポレイテッド 特定の化学的実体、組成物、および方法
TWI831739B (zh) * 2017-02-28 2024-02-11 日商大鵬藥品工業股份有限公司 使用吡唑并[3,4-d]嘧啶化合物之抗腫瘤效果增強劑
US12258376B2 (en) 2017-08-21 2025-03-25 Taiho Pharmaceutical Co., Ltd. Fusion protein of DCTN1 protein with RET protein
MY206124A (en) * 2019-01-11 2024-11-30 Taiho Pharmaceutical Co Ltd Pyrimidine compound or salt thereof
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
EP4079306A4 (en) * 2019-12-19 2024-01-10 Taiho Pharmaceutical Co., Ltd. THERAPEUTIC AGENT CONTAINING A PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4183395A4 (en) * 2020-07-15 2024-07-24 Taiho Pharmaceutical Co., Ltd. PYRIMIDINE COMPOUND-CONTAINING COMBINATION FOR USE IN TUMOR TREATMENT
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN114736207B (zh) * 2022-04-28 2023-03-31 武汉九州钰民医药科技有限公司 一种小分子her2抑制剂的制备工艺

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042556A1 (en) 2003-10-27 2005-05-12 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2007067781A2 (en) 2005-12-08 2007-06-14 Abbott Laboratories 9-membered heterobicyclic compounds as inhibitors of protein kinases
WO2007126841A2 (en) 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
EP2089391B1 (en) 2006-11-03 2013-01-16 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
ES2562215T3 (es) 2007-03-28 2016-03-03 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton
JP2009235057A (ja) 2007-10-31 2009-10-15 Santen Pharmaceut Co Ltd 血管新生阻害活性を有する新規インドール誘導体
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN103857396A (zh) 2011-07-13 2014-06-11 药品循环公司 布鲁顿酪氨酸激酶抑制剂
CN103717247B (zh) * 2011-07-15 2016-04-27 赛诺菲-安万特德国有限公司 药物输送装置
PT2657233E (pt) 2012-01-19 2014-10-24 Taiho Pharmaceutical Co Ltd Composto de alcinil-benzeno substituído nas posições 3 e 5 e um seu sal
CN104250250A (zh) * 2013-06-25 2014-12-31 苏州科捷生物医药有限公司 4-芳香胺基嘧啶类化合物及其抗肿瘤用途

Also Published As

Publication number Publication date
EP2947086A4 (en) 2016-06-22
PH12015502737B1 (en) 2018-08-31
US9580432B2 (en) 2017-02-28
WO2015022926A1 (ja) 2015-02-19
HK1217703A1 (zh) 2017-01-20
CN105452257B (zh) 2017-09-05
KR101828187B1 (ko) 2018-02-09
EP2947086A1 (en) 2015-11-25
US20160115168A1 (en) 2016-04-28
EP2947086B1 (en) 2018-01-03
RU2666349C2 (ru) 2018-09-07
KR20160038891A (ko) 2016-04-07
TWI585089B (zh) 2017-06-01
BR112016002069A2 (pt) 2017-08-01
TR201802875T4 (tr) 2018-03-21
PH12015502737A1 (en) 2016-03-07
PT2947086T (pt) 2018-03-09
CN105452257A (zh) 2016-03-30
RU2015156524A (ru) 2017-09-14
AU2014307437A1 (en) 2016-01-21
HUE036834T2 (hu) 2018-08-28
TW201536786A (zh) 2015-10-01
DK2947086T3 (en) 2018-03-19
MX360498B (es) 2018-11-05
NO2947086T3 (enExample) 2018-06-02
MY171831A (en) 2019-11-01
CA2921208C (en) 2018-02-20
BR112016002069B1 (pt) 2020-08-18
JPWO2015022926A1 (ja) 2017-03-02
MX2016001845A (es) 2016-05-16
CA2921208A1 (en) 2015-02-19
ES2661733T3 (es) 2018-04-03
AU2014307437B2 (en) 2016-12-15
PL2947086T3 (pl) 2018-06-29
SG11201600048VA (en) 2016-03-30

Similar Documents

Publication Publication Date Title
JP6035423B2 (ja) 新規な縮合ピリミジン化合物又はその塩
KR102058366B1 (ko) 축합 피리미딘 화합물 또는 그의 염
TW200835495A (en) Substituted 8-piperidinyl-2-pyridinyl-pyrimido[1,2-a] pyrimidin-6-one and 8-piperidinyl-2-pyrimidinyl-pyrimido[1,2-a] pyrimidin-6-one derivatives
JP6093485B2 (ja) 免疫疾患の予防及び／又は治療剤
TWI869674B (zh) 雜芳基衍生化合物及其用途
WO2019223777A1 (zh) 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用
AU2016213031A2 (en) Novel salt of fused pyrimidine compound and crystal thereof
HK40056552A (en) Prophylactic and/or therapeutic agent for immune diseases
HK1217703B (en) Novel fused pyrimidine compound or salt thereof
HK40056552B (zh) 免疫疾病的预防剂和/或治疗剂
HK1240121A1 (en) Prophylactic and/or therapeutic agent for immune diseases
HK1240121B (zh) 免疫疾病的预防剂和/或治疗剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160905

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20160905

TRDD Decision of grant or rejection written
A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20161006

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161025

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161031

R150 Certificate of patent or registration of utility model

Ref document number: 6035423

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250